Literature DB >> 33684939

Characterization of DLBCL with a PMBL gene expression signature.

Gerben Duns1,2, Elena Viganò1,2, Daisuke Ennishi1, Clementine Sarkozy1,3, Stacy S Hung1, Elizabeth Chavez1, Katsuyoshi Takata1, Christopher Rushton4, Aixiang Jiang1,2, Susana Ben-Neriah1, Bruce W Woolcock1, Graham W Slack1, Eric D Hsi5, Jeffrey W Craig1, Laura K Hilton1,4, Sohrab P Shah6,7, Pedro Farinha1, Anja Mottok1,8, Randy D Gascoyne1, Ryan D Morin4,9, Kerry J Savage1, David W Scott1, Christian Steidl1.   

Abstract

Primary mediastinal large B-cell lymphoma (PMBL) is a type of aggressive B-cell lymphoma that typically affects young adults, characterized by presence of a bulky anterior mediastinal mass. Lymphomas with gene expression features of PMBL have been described in nonmediastinal sites, raising questions about how these tumors should be classified. Here, we investigated whether these nonmediastinal lymphomas are indeed PMBLs or instead represent a distinct group within diffuse large B-cell lymphoma (DLBCL). From a cohort of 325 de novo DLBCL cases, we identified tumors from patients without evidence of anterior mediastinal involvement that expressed a PMBL expression signature (nm-PMBLsig+; n = 16; 5%). A majority of these tumors expressed MAL and CD23, proteins typically observed in bona fide PMBL (bf-PMBL). Evaluation of clinical features of nm-PMBLsig+ cases revealed close associations with DLBCL, and a majority displayed a germinal center B cell-like cell of origin (GCB). In contrast to patients with bf-PMBL, patients with nm-PMBLsig+ presented at an older age and did not show pleural disease, and bone/bone marrow involvement was observed in 3 cases. However, although clinically distinct from bf-PMBL, nm-PMBLsig+ tumors resembled bf-PMBL at the molecular level, with upregulation of immune response, JAK-STAT, and NF-κB signatures. Mutational analysis revealed frequent somatic gene mutations in SOCS1, IL4R, ITPKB, and STAT6, as well as CD83 and BIRC3, with the latter genes significantly more frequently affected than in GCB DLBCL or bf-PMBL. Our data establish nm-PMBLsig+ lymphomas as a group within DLBCL with distinct phenotypic and genetic features. These findings may have implications for gene expression- and mutation-based subtyping of aggressive B-cell lymphomas and related targeted therapies.
© 2021 by The American Society of Hematology.

Entities:  

Year:  2021        PMID: 33684939     DOI: 10.1182/blood.2020007683

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

Review 1.  The MAL Protein, an Integral Component of Specialized Membranes, in Normal Cells and Cancer.

Authors:  Armando Rubio-Ramos; Leticia Labat-de-Hoz; Isabel Correas; Miguel A Alonso
Journal:  Cells       Date:  2021-04-30       Impact factor: 6.600

2.  Optimizing outcomes in primary mediastinal B-cell lymphoma: is R-CHOP enough?

Authors:  Michael R Cook; Kieron Dunleavy
Journal:  Blood Adv       Date:  2021-10-12

Review 3.  Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment.

Authors:  Alexey V Danilov; Massimo Magagnoli; Matthew J Matasar
Journal:  Oncologist       Date:  2022-02-03

4.  Dose-adjusted EPOCH-R is not superior to sequential R-CHOP/R-ICE as a frontline treatment for newly diagnosed primary mediastinal B-cell lymphoma: Results of a bi-center retrospective study.

Authors:  Yael Morgenstern; Shlomzion Aumann; Neta Goldschmidt; Moshe E Gatt; Boaz Nachmias; Netanel A Horowitz
Journal:  Cancer Med       Date:  2021-11-24       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.